Beauty's prevailing narrative often frames skincare as a corrective response, something to consider only after visible aging sets in. DKGlow proposes a different theory, one that is embedded in the belief that maintenance, grounded in cellular science, should begin earlier and evolve with time.
Founded by Dr. Dorra Frikha, a PhD-trained scientist in bone mechanics, DKGlow is a biotech-driven skincare brand rooted in mitochondrial research. Frikha's doctoral work, she highlights, focused on mitochondrial osteocytes, bone cells, and the role of mitochondrial function in cell viability, particularly in estrogen-deficient, postmenopausal models. Her research explored how daily doses of FDA-approved methylene blue influenced oxidative stress and bone loss, forming the basis of a pending patent.
